Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited
Your view on PAR.AX
Overview
What the company does, where it operates, and who runs it.
About Paradigm Biopharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul John Rennie
- Headquarters
- 500 Collins Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul John Rennie
- Headquarters
- 500 Collins Street, Melbourne, VIC, AU
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health.
A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Paradigm Biopharmaceuticals Limited. Starting points for Paradigm Biopharmaceuticals Limited: EPS -AUD 0.16, beta -0.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Paradigm Biopharmaceuticals Limited. Paradigm Biopharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Paradigm Biopharmaceuticals Limited. Trailing twelve-month EPS for Paradigm Biopharmaceuticals Limited stands at -AUD 0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.08 | AUD 0.18 |
| Lowest estimate | −AUD 0.10 | AUD 0.07 |
| Highest estimate | −AUD 0.07 | AUD 0.29 |
| Number of analysts | 2 | 2 |
| A year ago | −AUD 0.151 | — |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 3.26M | AUD 321.90M |
| Lowest estimate | AUD 1.25M | AUD 123.50M |
| Highest estimate | AUD 5.27M | AUD 520.30M |
| Number of analysts | 2 | 2 |
| A year ago | AUD 80150.00 | — |
| Growth vs a year ago | +3967.4% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Paradigm Biopharmaceuticals Limited. Paradigm Biopharmaceuticals Limited has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| AHC.AXAustco Healthcare Limited | Healthcare | Medical - Instruments & Supplies | — | ||
| ALA.AXArovella Therapeutics Limited | Healthcare | Biotechnology | — | ||
| AVH.AXAVITA Medical, Inc. | Healthcare | Medical - Devices | — | ||
| EMV.AXEMVision Medical Devices Ltd | Healthcare | Medical - Devices | — | ||
| NYR.AXNyrada Inc. | Healthcare | Biotechnology | — | ||
| ONE.AXOneview Healthcare PLC | Healthcare | Medical - Healthcare Information Services | — | ||
| PEB.AXPacific Edge Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PALIPalisade Bio, Inc. | Healthcare | NASDAQ | $168.9M | ||
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.9M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.5B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $47,738 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $869 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $373.3M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.8M | ||
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $9.3B | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Paradigm Biopharmaceuticals Limited.